42.2 F
Huntsville
49.4 F
Muscle Shoals
48.3 F
Albertville
50.8 F
Fort Payne

Huntsville Heart Center pumped about partnership with Australian software firm

HUNTSVILLE – The Huntsville Heart Center, which treats more than 80,000 cardiac patients per year, has announced a clinical partnership with Australia-based Artrya. The initial agreement includes a comparison study of patient cardiac CT scans read by experts, and those read by AI-based technology.

Also, as part of the initial agreement, Heart Center Research, a division of Huntsville Heart Center, will conduct a study to determine the efficacy of Artrya’s  AI-based cardiac software solution Artrya Salix.

“I am delighted and honored to lead a team of Heart Center physicians who will compare the heart scans of patients to see if we can validate the accuracy of Artrya Salix AI software in identifying coronary artery disease and specifically high-risk plaque as compared to human readers,” said Dr. Michael L. Ridner, cardiologist and principal investigator of the study. “AI technology like this holds the potential to change the way we practice medicine, and in this instance, may help us save lives. The Heart Center team is excited to be on the ground floor in evaluating Artrya’s potential.”

The multi-scanner retrospective study will utilize Artrya’s core solution Salix Coronary Anatomy, an AI-based technology capable of analyzing cardiac CT scans to report coronary disease biomarkers, including components of high-risk plaque.

In the study, Heart Center researchers use CT scans obtained for clinical purposes. The scans will be uploaded to cloud-based Salix, which will interpret them using Artrya-proprietary software.

Artrya USA Co-CEOs Jory Tremblay and Ted Schwab said they are excited about their company’s first clinical partnership in the U.S.

“We are pleased that such a well-regarded heart center has joined in our mission to create better detection of the world’s leading killer — heart disease,” they said in a joint statement.

The clinical trial is expected to be complete by October and Tremblay and Schwab will provide validation of the technology so it can pave the way for commercial use in the United States.

Don’t miss out!  Subscribe to our email newsletter to have all our smart stories delivered to your inbox.

- Advertisment -

Most Popular